Jazz Pharmaceuticals Plc zgłasza patent na preparat CBD zawierający 90% CBD i THC – połączenie z programem dotyczącym medycznej marihuany

Według profilu firmy GlobalData na Farmaceutyka jazzowa, Cancer treatment biomarkers was a key innovation area identified from patents. Farmaceutyka jazzowaudział dotacji w lutym 2024 r. wyniósł 47%. Udział grantów opiera się na stosunku liczby grantów do całkowitej liczby patentów.

Cbd preparation with at least 90% cbd and thc

A recently granted patent (Publication Number: US11865102B2) discloses a cannabidiol (CBD) preparation with a high concentration of CBD, greater than or equal to 90% (w/w) based on the total amount of cannabinoids in the preparation. The remaining cannabinoids in the preparation include tetrahydrocannabinol (THC), present as a mixture of trans-THC and cis-THC, with a specific ratio ranging from about 0.7:1.0 to about 5.0:1.0. Additionally, the CBD preparation contains not more than 1.5% (w/w) THC, with specific ranges of THC content specified in the claims.

Furthermore, the patent covers the use of this CBD preparation in pharmaceutical compositions for treating epilepsy, specifically targeting conditions such as Dravet syndrome, Lennox Gastaut syndrome, Doose syndrome, or tuberous sclerosis complex (TSC). The method involves administering a therapeutically effective amount of the CBD preparation, with specified dosage ranges from about 5 mg/kg/day to…